Medical Research

At CAF, Medical Research is Key

Medical researchers who are interested in initiating a thalassemia-related project or who have an existing project that requires additional funding: The Cooley’s Anemia Foundation may be just what you need.

CAF has a decades-long history of supporting innovative and important research in thalassemia. Our established and respected Medical Fellowship program has funded numerous early career individuals who have continued to stay in the thalassemia field and make important contributions to the scientific and clinical study of thalassemia.

Our Support for Ongoing Clinical Research in Thalassemia Grants and Clinical Trials in Thalassemia Cell and Gene Therapy Grants are aggressively pushing forward the understanding of issues of concern to the growing thalassemia population and helping to propel advances in areas of primary importance.


THALASSEMIA CARE WALK 2024 – Locations & Info!

Thalassemia Care Walk

Care Walk is the Cooley’s Anemia Foundation’s annual fundraising event and opportunity to bring together the thalassemia community and its supporters around the country. Funds raised support medical research to fight thalassemia, a genetic blood disorder, as well as patient support services for thalassemia patients across the country. Click here to register for Care Walk!! […]

Read more


FDA Approves Vertex & CRISPR’s Gene Editing Therapy to treat Beta Thalassemia

Treat Beta Thalassemia

The FDA has approved Vertex and CRISPR’s gene-editing therapy Casgevy to treat beta thalassemia. Casgevy becomes the first therapy for the rare blood disorder to use the innovative CRISPR gene-editing technology. Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta thalassemia (TDT). The approval […]

Read more


Agios Pharmaceuticals Announces Phase 3 ENERGIZE – Treatment for Thalassemia Patients

Phase 3 ENERGIZE

Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia January 3, 2024 – Agios Pharmaceuticals, Inc. today announced that the global Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary endpoint of […]

Read more


Thalassemia Care Walk Location Directory

Thalassemia Care Walk 2023 Locations

Care Walk is the Cooley’s Anemia Foundation’s annual fundraising event and opportunity to bring together the thalassemia community and its supporters around the country. Funds raised support medical research to fight thalassemia, a genetic blood disorder, as well as patient support services for thalassemia patients across the country. Your Walk, Your Way! Care Walk is set up […]

Read more


CAF Accepting Applications for 2024- 2025 Medical Research Grants & Fellowships

Fellowships & Grants in Thalassemia research

The Cooley’s Anemia Foundation is accepting applications for medical research grants and fellowships in areas related to thalassemia. The awards are in three categories: Clinical Trials in Thalassemia Cell & Gene Therapy Clinical Research Application Research Fellowship Application Details are as follows: CLINICAL TRIALS IN THALASSEMIA CELL AND GENE THERAPY The Cooley’s Anemia Foundation invites […]

Read more


CAF Awards $200,000 in Medical Research Fellowships

We’re proud to announce two new Cooley’s Anemia Foundation Medical Research Fellowships and two renewal Medical Research Fellowships for the 2023-2024 grant cycle. The total amount of funding for the two research Fellowships is $200,000. These Fellowship recipients were assessed on the basis of the quality of the scientific content, the academic accomplishments and future […]

Read more





FDA Approves bluebird bio’s ZYNTEGLO®, the First Gene Therapy for People with Transfusion-Dependent Beta-Thalassemia

zynteglo approved for beta-thalassemia

bluebird bio, Inc. announced the FDA has approved ZYNTEGLO®, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell transfusions.

Read more


Secured By miniOrange